

SUPPLEMENTARY PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP $\,02\,$ 78 $\,3816\,$ shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of document with indication, where appropriate, of relevant passages P,X WO 02/47474 A (SUMITOMO PHARMACEUTICALS COMPANY) 20 June 2002 (2002-06-20) * abstract; sequences 15,16 * P,X GOTOH MASASHI ET AL: "Development of HLA-A2402/K(b) transgenic mice." INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 10 AUG 2002, vol. 100, no. 5, 10 August 2002 (2002-08-10), pages	15,19-22 1-11,14,	CLASSIFICATION OF THE APPLICATION (Int.Cl.7) C07 K7/06 C07 K16/18 C12N5/08 A61K38/04 A61K39/395 A61P35/00 G01N33/15				
P,X WO 02/47474 A (SUMITOMO PHARMACEUTICALS COMPANY) 20 June 2002 (2002-06-20) * abstract; sequences 15,16 * P,X GOTOH MASASHI ET AL: "Development of HLA-A2402/K(b) transgenic mice." INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 10 AUG 2002, vol. 100, no. 5, 10 August 2002 (2002-08-10), pages	to claim 1-11,14, 15,19-22 1-11,14,	C07K7/06 C07K16/18 C12N5/08 A61K38/04 A61K39/395 A61P35/00 G01N33/15				
COMPANY) 20 June 2002 (2002-06-20) * abstract; sequences 15,16 * P,X GOTOH MASASHI ET AL: "Development of HLA-A2402/K(b) transgenic mice." INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 10 AUG 2002, vol. 100, no. 5, 10 August 2002 (2002-08-10), pages	15,19-22 1-11,14,	C07K16/18 C12N5/08 A61K38/04 A61K39/395 A61P35/00 G01N33/15				
HLA-A2402/K(b) transgenic mice." INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 10 AUG 2002, vol. 100, no. 5, 10 August 2002 (2002-08-10), pages		A61K39/395 A61P35/00 G01N33/15				
565-570, XP002338265 ISSN: 0020-7136 * the whole document *		G01N33/50 G01N33/53 G01N33/566				
		TECHNICAL FIELDS SEARCHED (Int.CI.7) A61K C12N C07K				
The supplementary search report has been based on the last set of claims valued and available at the start of the search.	id	G01N				
INCOMPLETE SEARCH						
The Search Division considers that the present application, or some or all of its claims, doe not comply with the EPC to such an extent that a meaningful search into the state of the art be carried out, or can only be carried out partially, for the following claims: Claims searched completely:						
Claims searched incompletely :						
Claims not searched :						
Reason for the limitation of the search:						
see sheet C						
Place of search Date of completion of the search		Examiner				
The Hague 28 July 2005	Mor	eau, J				
CATEGORY OF CITED DOCUMENTS T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filling date Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filling date D: document cited in the application L: document cited for other reasons A: technological background S: member of the same patent family, corresponding						

EPO FORM 1503 03.82 (P04C20)

1



INCOMPLETE SEARCH SHEET C

Application Number EP 02 78 3816

Although claim 9, as far it concerns a in vivo method is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Claim(s) searched completely: 1-15, 20-22

Claim(s) searched incompletely:

Claim(s) not searched: 16-18

Reason for the limitation of the search:

Present claims 16-18 and 19 partly relate to a compound defined by reference to a desirable characteristic or property, namely enhancing the recognition of the peptide of claim 3 or 4 by an HLA-A24-restricted CTL, or the use of these compounds in a pharmaceutical composition.

The claims cover all compounds having this characteristic or property, whereas the application does not provide support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for any specific such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 02 78 3816

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-07-2005

Patent documer cited in search rep	t ort	Publication date		Patent family member(s)		Publication date
WO 0247474	A	20-06-2002	AU WO US	2261002 0247474 2005050580	A1 A1	24-06-200 20-06-200 03-03-200
		fficial Journal of the Euro				



专利名称(译)	肿瘤抗原					
公开(公告)号	EP1462456A4	公开(公告)日	2005-09-21			
申请号	EP2002783816	申请日	2002-12-10			
[标]申请(专利权)人(译)	伊藤KYOGO					
申请(专利权)人(译)	伊藤,KYOGO					
当前申请(专利权)人(译)	伊藤,KYOGO					
[标]发明人	ITOH KYOGO					
发明人	ITOH, KYOGO					
IPC分类号	A61K39/00 A61P35/00 C07K7/06 C07K16/30 C12N5/08 C12N9/64 G01N33/50 G01N33/574 C07K16 /18 A61K38/04 A61K39/395 G01N33/15 G01N33/53 G01N33/566					
CPC分类号	A61K39/00 A61K39/0011 A61P13/08 A61P35/00 A61P43/00 C07K7/06 C07K16/3069 G01N33/505 G01N33/57434 G01N2500/00 A61K39/001194 A61K39/001195					
优先权	2001376415 2001-12-10 JP					
其他公开文献	EP1462456A1					
外部链接	Espacenet					

摘要(译)

基于PSA,PSM和PSCA的氨基酸序列,鉴定了以HLA-A2限制或HLA-A24限制的方式从前列腺癌患者的外周血单核细胞中诱导CTL的肿瘤抗原肽。被称为前列腺癌标志物的蛋白质。还公开了具有被HLA-A2限制性CTL或HLA-A24限制性CTL识别的具有肿瘤抗原功能的肽,针对该肽的抗体,与该肽具有相互作用的化合物,一种诱导CTL的试剂。包括肽,包括其一种或多种的药物组合物,用于鉴定与该肽具有相互作用的化合物的方法,使用该肽诱导CTL的方法,一种用于测量该肽和抗体的方法以及用于鉴定方法或测量方法的试剂盒。

